Sorting through confusing messages: The art of HAART

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue SUPPL. 1, 2002, Pages

  Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INFECTION RISK; LYMPHOCYTE COUNT; OSTEOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT PLANNING; VIRUS REPLICATION;

EID: 0036738811     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200209011-00002     Document Type: Conference Paper

References (24)

1. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998; 47 (No. RR-5) Updated as a Living Document on February 4, 2002. Available from the HIV/AIDS Treatment Information Service website http://www. hivatis.org.
2. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel. JAMA 2000;283:381-90.
3. Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up of study 006 [abstract 224]. Presented at the 1st International AIDS Society Conference on HIV Treatment and Pathogenesis, Buenos Aires, Argentina, July 8-11, 2001. Available at: http://www.ias.se/abstract/show.asp?abstract_id = 224. Accessed May 6, 2002.
4. Mannerheimer S, Friedland G, Matts J, et al. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time [abstract TuOrB421]. Presented at the XIII International AIDS Conference, Durham, South Africa, July 9-14, 2000. Abstracts-On-Disk, XIII International AIDS Conference [CD-ROM] published by Merck Sharp & Dohme.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
6. + lymphocyte count <200 cells/mL) is associated with increased risk of death [abstract 520]. Presented at 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/520.htm. Accessed February 19, 2001.
7. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001;15:2251-7.
8. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
9. Skowron G, Street JC, Obee EM. Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28: 313-9.
10. Ledergerber B, Egger M, Opravil M. et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
11. Eron JJ Jr, Vernazza P. Alternative strategies for anti-HIV treatment. AIDS 2001;15(Suppl 5):S161-9.
12. Hodder S, Burtcel B, Kawabata H, et al. Coronary heart disease in patients with human immunodeficiency virus [abstract 223]. Presented at the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece, October 23-26. 2001.
13. Tebas P, Henry K, Nease R, et al. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS 2001;15:591-9.
14. Schrader S, Sharma S, Seekins D, et al. Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily [abstract 318]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/318.htm. Accessed May 15, 2001.
15. Gathe J, Badaro R, Grimwood A, et al. Comparison of a triple combination regimen containing an enteric-coated formulation of didanosine administered once daily versus a regimen of Combivir plus nelfinavir [abstract 319]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www. retroconference.org/2001/abstracts/abstracts/abstracts/319.htm. Accessed March 17, 2002.
16. Fischl M, Burnside A, Farthing C, et al. Efficacy of Combivir (COM) (lamivudine 150 mg/zidovudine 300 mg) plus Ziagen (abacavir (ABC) 300 mg) BID compared to Trizivir (TZV) (3TC 150 mg/ZDV 300 mg/ABC 300 mg) BID in patients receiving prior COM plus ABC [abstract 315]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/315.htm. Accessed March 17, 2002.
17. Sension M, Bellos N, Johnson J, et al. Efficacy and safety of switch to 3TC 300 mg QD vs. continued 3TC 150 mg BID in subjects with virologic suppression on stable 3TC/d4T/PI therapy (COLA4005): final 24-week results. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/317.htm. Accessed February 22, 2002.
18. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001;6: 249-53.
19. Brundage RC, Kline MW, Lindsey J, et al. Pharmacokinetics of saquinavir (SQV) with nelfinavir (NFV) or ritonavir (RTV) in HIV-infected children [abstract 728]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/728.htm. Accessed June 19, 2001.
20. Degen O, Kurowski M, van Lunzen J, et al. Amprenavir (APV) and ritonavir (RTV): intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/739.htm. Accessed April 26, 2001.
21. Lamotte C, Peytavin G, Perre P, et al. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentration in four different ritonavir (RTV)-IDV-containing regimens in HIV-infected patients [abstract 738]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-9, 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/738.htm. Accessed April 26, 2001.
22. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407: 523-6.
23. Tebas P, Henry K, Mondy K, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in HIV-infected patients: implications for pulse therapy strategies. J Infect Dis 2002, in press.
24. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001;98:15161-6.